Nitromint (Glyceryl Trinitrate Solution)

Glyceryl trinitrate releases nitric oxide in the body, which activates guanylate cyclase and raises cyclic GMP levels in vascular smooth muscle. This biochemical cascade causes relaxation of the muscle, leading to dilation of coronary and peripheral vessels, improved blood flow, and reduced cardiac oxygen demand.

The specific dose of Nitromint is determined by the prescribing clinician based on the patient’s condition, severity of symptoms, and response to therapy. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

The safety of Nitromint in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order Nitromint, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nitromint belongs to the nitrate class, offering rapid onset of action for acute chest pain, whereas beta‑blockers and calcium‑channel blockers provide longer‑term control. Unlike some alternatives, nitrates can cause tolerance with continuous use, so dosing schedules often include drug‑free intervals to maintain effectiveness.

Nitromint should be stored at ambient temperature below 25 °C, in its original container, protected from moisture and direct light. Keep the solution out of reach of children and avoid shaking the vial, as it is formulated for sublingual administration.

Nitromint is a sublingual solution. The patient places the prescribed number of drops under the tongue and allows it to dissolve completely without swallowing. This route provides rapid absorption into the bloodstream, delivering quick relief of anginal symptoms.

The most serious risks associated with Nitromint include severe hypotension, syncope, methemoglobinemia, and allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience fainting, profound dizziness, bluish skin discoloration, or signs of an allergic response.

Nitromint should be avoided in patients with known hypersensitivity to nitrates, those who have taken phosphodiesterase‑5 inhibitors (e.g., sildenafil) within the past 24 hours, and individuals with severe hypotension, closed‑angle glaucoma, or a recent history of severe aortic stenosis unless specifically directed by a physician.